The development of a medication to treat illness from Ebola will be accelerated under a contract with the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR). This contract supports the government-wide response to the Ebola outbreak in West Africa.
British, Hungarian and Austrian police were involved in the sweep that culminated Monday in...
Years before Burger King sized up a Canadian headquarters in a hunt for lower taxes, Republican...
Wako Chemicals' Cape Charles facility extracts the naturally pale blue blood of horseshoe crabs...
Introducing an economical and simple-to-use stainless steel tablet hardness tester that accurately calculates the hardness and thickness of solid dosage forms.
The line of Gastec pumps and detector tubes precisely measure gases and vapors in over 600 applications, making it a suitable tool for gas detection and measurement as well as detecting leaks and fugitive emissions.
Introducing the ECX-001 Case Packer, a jointly-developed semi-automatic case packer with unit-level serialization capabilities that has been outfitted with best in class software, cameras, and printers to meet the more stringent track & trace requirements mandated by the Drug Quality and Security Act.
Particle Sciences Expands Drug Eluting Device Capabilities and Overall Clinical Trial Manufacturing ResourcesSeptember 2, 2014 2:39 pm | News | Comments
Particle Sciences, a CDMO for drug eluting devices, has added to its investment in development and manufacturing capabilities with the addition of a new 18mm extruder. The company now has over 6000ft2 of operating cleanroom and cGMP warehouse space including ISO5 (sterile) and two dedicated highly potent suites.
Actavis plc today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Actavis' New Drug Application (NDA) for eluxadoline, an investigational drug for the treatment of diarrhea and abdominal pain in men and women with diarrhea predominant Irritable Bowel Syndrome (IBS-D).
Doctors say that new treatment could be a big breakthrough to help those affected by the condition.
EMD Serono announced today that Drew Young has joined the company as Senior Vice President, Neurology and Immunology. In this capacity, he will be responsible for leading the strategic direction of the U.S. Neurology and Immunology franchise, including future products.
Regeneca Worldwide a division of VivaCeuticals, Inc. Las Vegas, NV is expanding the voluntary nationwide recall of its RegeneSlim appetite control dietary supplement to include lot #823230415, lot #EX0616r 15813, Lot # EX0616R15814 and Lot #11414re5516 because FDA analysis confirmed the presence of DMAA.
Zogenix today announced new post-hoc analysis data showing that the indicated 12-hour dose of Zohydro(R) ER,(hydrocodone bitartrate) Extended-Release Capsules, CII, provided durable pain relief over the entire dosing interval.
The monkeys were given the drug, ZMapp, three to five days after they were infected with the virus and when most were showing symptoms. That is several days later than any other experimental Ebola treatment tested so far.
Foreign companies in China feel increasingly targeted for unfair enforcement of anti-monopoly and other laws and might cut investment if conditions fail to improve, a U.S. business group said Tuesday.
Pfizer and Protalix BioTherapeutics announced that the FDA approved ELELYSO™ for injection for pediatric patients. ELELYSO is therefore now indicated for long-term enzyme replacement therapy (ERT) for adult and pediatric patients with a confirmed diagnosis of Type 1 Gaucher disease.
DPx Holdings B.V., privately owned by JLL Partners and Royal DSM, has reached a definitive agreement to acquire all shares of Gallus BioPharmaceuticals, LLC, a contract manufacturing company specializing in biologics and current portfolio company of Ridgemont Equity Partners.
Introducing Steritest™ Symbio Pumps for easier, safer and more reliable sterility testing of pharmaceutical products in laminar flow hoods, isolators and clean rooms.
The facility was established in 1989, expanded in 2003-2006 and acquired by Olympus Biotech in 2011. It has been used primarily for mammalian cell manufacturing until production was phased out earlier this year.